Copyright
©The Author(s) 2015.
World J Hepatol. Mar 27, 2015; 7(3): 521-531
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Table 4 Overall survival in the second cohort of patients using the ART score calculated before the second TACE with a cut-off value of: 0-1.5 vs≥ 2.5
| ART(n = 82) | ART[0](n = 39) | ART[1](n = 14) | ART[1.5](n = 5) | ART[2.5](n = 1) | ART[3](n = 3) | ART[4](n = 5) | ART[5](n = 10) | ART[5.5](n = 1) | ART[8](n = 4) |
| Median-survival,mo (95%CI) | 27(22-38) | 11(7-18) | 15(11-50) | N/A | 10(3-31) | 31(8-31) | 8(7-12) | N/A | 8(4-23) |
| 22 (15-27) | 10 (8-23) | ||||||||
| Pvalue ART (0, 1.5)vsART≥2.5 | 0.07 | ||||||||
- Citation: Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol 2015; 7(3): 521-531
- URL: https://www.wjgnet.com/1948-5182/full/v7/i3/521.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i3.521